

# **nlmixr: pharmacometric modelling for the people**

PKUK 2022

Rik Schoemaker, PhD

On behalf of the nlmixr development team:  
Matt Fidler, Bill Denney, Richard Hooijmaijers,  
Rik Schoemaker, Mirjam Trame, Justin Wilkins,  
Yuan Xiong, John Harrold, Huijuan Xu



# History

- **2015:** Melissa Hallow's PAGE 2015 poster on RxODE<sup>1</sup> mentions parameter estimation with nlme
- **2015:** Wenping Wang implements parameter estimation using nlme (R-package) and SAEM from scratch
- **2016:** Yuan Xiong writes PMXStan<sup>2</sup> linking RxODE and stan
- **October 2016:** first public release of nlmixr
- **December 2016:** nlmixr presentation in Uppsala where Mats Karlsson mentions Almquist et al<sup>3</sup> implementing FOCEi
- **January 2017:** Matt Fidler joins the team and implements FOCEi
- **June 2017:** unified user interface
- **October 2017:** first pre-release nlmixr on CRAN
- **August 2018:** nlmixr 1.0 on CRAN
- **September 2019:** nlmixr tutorial in CPT:PSP<sup>4</sup>
- **November 2019:** paper in CPT:PSP comparing nlmixr FOCEi to NONMEM, nlmixr SAEM to Monolix<sup>5</sup>
- **April 2021:** nlmixr version 2.0 on CRAN no longer needs Python, hugely simplifying life!
- **June 2022:** nlmixr2 and rxode2 on CRAN

<sup>1</sup><https://www.page-meeting.org/default.asp?abstract=3542>

<sup>2</sup><https://discuss.go-isop.org/t/introduction-to-pmxstan-an-r-library-to-facilitate-pkpd-modeling-with-stan/554>

<sup>3</sup><https://pubmed.ncbi.nlm.nih.gov/25801663/>

<sup>4</sup><https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/psp4.12445>

<sup>5</sup><https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930853/>

# The nlmixr team

Founder, Emeritus



Wenping Wang, PhD

nlmixr Team Lead



Matthew Fidler, PhD



Bill Denney, PhD



John Harrold, PhD



Mirjam Trame, PhD



Rik Schoemaker, PhD



Teun Post, PharmD, PhD



Richard Hooijmaijers, BSc



Justin Wilkins, PhD



Yuan Xiong, PhD

# Motivation

## • ~~Commercial gain~~

- Commercial gain is not a motivation for this project. Pharmacometrics is a small community and therefore to make a commercial software product is very risky, and when you succeed will need to be very expensive to recoup investments
- By starting out not wanting to make money but have motivation from other sources, the project becomes attractive to members with other mentalities, and allows setting up a team you would never get for a commercial project

# Motivation

- **Curiosity:** can we actually pull this off?
  - The attraction of inventing something new, to venture where no-one has succeeded (in R that is)

# Motivation

- **Curiosity:** can we actually pull this off?
- **Consolidation:** testing, checking, documenting
  - Not very sexy, but an essential task to support the inventor
  - Attractive to those team members that like to be sure everything works properly!

# Motivation

- **Curiosity:** can we actually pull this off?
- **Consolidation:** testing, checking, documenting
- **Convenience:** parameter estimation in R
  - To have both input, analysis and output in a single package is super-attractive and makes workflows potentially very efficient

# Motivation

- **Curiosity:** can we actually pull this off?
- **Consolidation:** testing, checking, documenting
- **Convenience:** parameter estimation in R
- **Collaboration:** open-source encourages other to contribute
  - Where open-science allows you to ‘stand on the shoulder of giants’, open-source allows everyone to take the software and run with it, creating applications you would never think of before



# Collaboration: projects so far

- **ShinyMixR**: shiny app for interactively running nlmixr (Richard Hooijmaijers)
- **xpose.nlmixr**: diagnostics using xpose (Justin Wilkins)
- **ggPMX**: diagnostics and reporting (Irina Baltcheva and Bruno Bieth)

Under development:

- **nlmixr2rpt**: automatic and scripted reporting (John Harrold)
- **babelmixr**: nlmixr as front-end to NONMEM and Monolix (Bill Denney and Matt Fidler)
  - PKNCA provides initial estimates
  - Unit conversion and implementation in code
  - Advanced diagnostics when NONMEM fails to run correctly

# Motivation

- **Curiosity:** can we actually pull this off?
- **Consolidation:** testing, checking, documenting
- **Convenience:** parameter estimation in R
- **Collaboration:** open-source encourages other to contribute
- **Concern:** continuity of existing software
  - What will happen to NONMEM when Bob Bauer retires? Having a backup solution is very reassuring

# Motivation

- **Curiosity:** can we actually pull this off?
- **Consolidation:** testing, checking, documenting
- **Convenience:** parameter estimation in R
- **Collaboration:** open-source encourages other to contribute
- **Concern:** continuity of existing software
- **Cost:** modelling software is expensive and limits use when funds are restricted
  - Free software makes modelling accessible in lower to middle income countries
  - Not needing a license makes giving courses much easier, and many pharmacometrics courses are already using nlmixr
  - Academic licenses appear to solve the issue of cost, but usually cannot be applied for commercial work making drug development in a low income environment difficult

# Motivation

- **Curiosity:** can we actually pull this off?
- **Consolidation:** testing, checking, documenting
- **Convenience:** parameter estimation in R
- **Collaboration:** open-source encourages other to contribute
- **Concern:** continuity of existing software
- **Cost:** modelling software is expensive and limits use when funds are restricted
- **Community:** non-linear mixed effect modelling available for everyone
  - Truly pharmacometric modelling for the people
  - Highly motivating to be able to help others
  - Many nlmixr courses have already been taught, and many publications are out there
  - Multiple teams are already using nlmixr for all their work (e.g. Joe Standing's group at UCL)

# Community

- **nlmixr courses:**

- PAGE (Montreux, Stockholm, Ljubljana)
- ACoP (San Diego, Denver)
- WCoP (Cape Town)
- PAGANZ (Queenstown)
- RedIF (Mexico, Uruguay)
- Cuba (3 courses)

- **publications:**

- 3 nlmixr publications from the nlmixr team
- 45 publications and counting using nlmixr

# Future

- Further nlmixr development:
  - Log-likelihood based parameter estimation (odd-type data)
  - Inter-occasion variability
  - Mixture models
  - Parallelisation FOCEi
- Setting up an advisory board
  - Keeps the nlmixr development team grounded in practice
  - Guides us on the direction forward
  - Helps consolidate the support base